We have recently formed a team (Qubigen) and have interest in collaborative opportunities with Research Institutes developing novel small-molecule drugs, for cancer, inflammatory and other diseases.

https://www.qubigen.com

Qubigen can offer its unique AI-based infrastructure and computational tools to generate high quality drug candidates for specific protein targets.

Qubigen uses a unique combination of algorithms to assess and screen novel compounds, based on molecular mechanics and quantum chemistry.

Qubigen uses Federated AI methodology, where the AI securely draws insights from data without ever moving or visualizing the data, avoiding any risk of exposing sensitive intellectual property.

If you are in an Institute and there is an early drug design (SAR) project, early in the drug development pipeline, we are interested in applying our novel Federated AI techniques and algorithms to your benefit so we can have a few more case studies under our belt.

Further information available on request.